Navigation

Eldisine

Eldisine - General Information

Vinblastine derivative with antineoplastic activity against cancer. Major side effects are myelosuppression and neurotoxicity. Eldisine is used extensively in chemotherapy protocols (antineoplastic combined chemotherapy protocols). [PubChem]

 

Pharmacology of Eldisine

Eldisine is indicated for the treatment of acute lymphocytic leukemia of childhood that is resistant to vincristine and non-oat cell lung cancer.Eldisine causes the arrest of cells in metaphase mitosis. It is three times more potent than vincristine and nearly 10 times more potent than vinblastine in causing mitotic arrest in in vitro studies at doses designed to arrest from 10 to 15% of the cells in mitosis. Eldisine and vincristine are approximately equipotent at dose levels that arrest 40 to 50% of the cells in mitosis. Unlike vinblastine, vindesine produces very few postmetaphase cells. Eldisine has demonstrated activity in patients who have relapsed while receiving multiple-agent treatment that included vincristine.

 

Eldisine for patients

The treatmewnt with Vindesine can cause hair, but it is usually reversible. It may also cause loss of sensation or tingling in hands or feet, fever, chill, sore throat, constipation, black stool, bruising or bleeding.

Patients should be informed that the major acute toxicities of Vindesine are related to bone marrow toxicity, specifically granulocytopenia with increased susceptibility to infection. They should be advised to report fever or chills immediately. Women of childbearing potential should be advised to avoid becoming pregnant during treatment. Patients should be advised to contact their physician if they experience increased shortness of breath, cough, or other new pulmonary symptoms, or if they experience symptoms of abdominal pain or constipation.

 

Eldisine Interactions

Vindesine can interact with the drugs of the following categories:

  • Blood dyscrasia: can cause unpredictable myelotoxicity
  • Bone marrow depressants: can cause a predictable dose-related myelotoxicity
  • Radiation therapy: may cause marrow depression
  • Neurotoxic medications: can cause neurologic toxicity
  • Phenytoin: can increase seizure activity
  • Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine
  • Mitomycin-C: may cause shortness of breath and bronchospasm
  • Killed virus vaccines: may decrease patient's response to the vaccine

 

Eldisine Contraindications

Vindesine is contraindicated in patients who are known hypersensitive to Vindesine, vinca alkaloids, or any component of the formulation.

 

Additional information about Eldisine

Eldisine Indication: For the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis
Mechanism Of Action: Eldisine acts by causing the arrest of cells in metaphase mitosis through its interaction with tubulin. The drug is cell-cycle specific for the S phase.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Vindesine
Synonyms: Vindesine Sulfate; Desacetylvinblastine Amide Sulfate
Drug Category: Antineoplastic Agents
Drug Type: Small Molecule; Approved

Other Brand Names containing Vindesine: DAVA; Eldesine; Eldisine;
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: 65-75%
Biotransformation: Hepatic
Half Life: 24 hours.
Dosage Forms of Eldisine: Solution Intravenous
Chemical IUPAC Name: Not Available
Chemical Formula: C43H55N5O7
Vindesine on Wikipedia: https://en.wikipedia.org/wiki/Vindesine
Organisms Affected: Humans and other mammals